Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

HKG:1349 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,223	1,147	1,056	1,196	1,289	1,209
Short-Term Investments	-	-	-	-	30	-
Cash & Short-Term Investments	1,223	1,147	1,056	1,196	1,319	1,209
Cash Growth	10.53%	8.60%	-11.67%	-9.35%	9.13%	-13.46%
Accounts Receivable	285.5	297.75	469.96	620.49	679.12	672.49
Other Receivables	1.02	0.31	1.08	0.16	5.14	1.18
Receivables	286.52	298.07	471.04	620.64	684.26	673.66
Inventory	28.19	33.21	47.27	43.65	40.53	35.63
Other Current Assets	2.07	7.16	32.18	9.24	25.1	9.77
Total Current Assets	1,540	1,486	1,607	1,869	2,069	1,928
Property, Plant & Equipment	453.72	477.25	503.53	475.33	351.51	301.92
Long-Term Investments	224.97	229.07	257.49	287.53	306.37	327.86
Other Intangible Assets	54.4	60.87	68.65	86.35	62.32	88.46
Long-Term Deferred Tax Assets	131.41	131.41	133.28	100.87	85.9	79.22
Long-Term Deferred Charges	6.28	4.41	9.28	-	43.09	36.12
Other Long-Term Assets	2.82	2.12	7.5	57.18	57.62	19.64
Total Assets	2,413	2,391	2,587	2,877	2,976	2,781

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12.3	6.07	10.67	8.05	7.43	8.17
Accrued Expenses	177.81	171.35	167.57	36.86	34.67	53.78
Short-Term Debt	-	-	-	-	101	-
Current Portion of Leases	5.44	5.35	6.1	6.33	8.22	8.68
Current Income Taxes Payable	-	-	-	1.61	1.63	10.4
Current Unearned Revenue	4.68	5.41	8.34	0.26	0.31	348.87
Other Current Liabilities	35.73	57.45	58.27	451.9	520.09	98.3
Total Current Liabilities	235.97	245.62	250.95	505.02	673.34	528.2
Long-Term Leases	6.54	9.34	14.43	10.95	15.6	22.59
Long-Term Unearned Revenue	17.89	18.97	15.85	2.15	34.04	40.8
Total Liabilities	260.4	273.93	281.23	518.12	722.99	591.58

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	103.66	103.66	103.66	103.66	102.9	104.3
Additional Paid-In Capital	1,290	1,290	1,290	1,289	1,225	1,265
Retained Earnings	765.26	728.37	916.9	970.46	934.39	868.43
Treasury Stock	-	-	-	-	-	-40.82
Comprehensive Income & Other	-6.64	-6.05	-5.55	-5.86	-5.2	-4.05
Total Common Equity	2,153	2,116	2,305	2,358	2,257	2,193
Minority Interest	0.31	0.43	0.71	1.01	-4.08	-3.36
Shareholders' Equity	2,153	2,117	2,305	2,359	2,253	2,190
Total Liabilities & Equity	2,413	2,391	2,587	2,877	2,976	2,781

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	11.99	14.69	20.53	17.28	124.81	31.26
Net Cash (Debt)	1,211	1,132	1,036	1,179	1,194	1,178
Net Cash Growth	11.18%	9.33%	-12.12%	-1.33%	1.43%	-14.49%
Net Cash Per Share	1.17	1.09	1.00	1.14	1.16	1.13
Filing Date Shares Outstanding	1,037	1,037	1,037	1,037	1,029	1,032
Total Common Shares Outstanding	1,037	1,037	1,037	1,037	1,029	1,032
Working Capital	1,304	1,240	1,356	1,364	1,396	1,400
Book Value Per Share	2.08	2.04	2.22	2.27	2.19	2.12
Tangible Book Value	2,098	2,055	2,236	2,271	2,195	2,104
Tangible Book Value Per Share	2.02	1.98	2.16	2.19	2.13	2.04
Buildings	397.18	396.73	368.53	199.22	198.52	198.52
Machinery	497.79	500.03	504.91	388.63	341.74	322.86
Construction In Progress	0.59	0.19	7.2	229.96	122.37	48.9

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error